Kabir Mody, MD discusses new directions with yttrium-90 glass microspheres in hepatocellular carcinoma as demonstrated in the retrospective LEGACY study.
Kabir Mody, MD
Advertisement
Articles by Kabir Mody, MD
Kabir Mody, MD, discusses the unique approach used to deliver Y-90 glass microspheres to patients with unresectable hepatocellular carcinoma.
Kabir Mody, assistant professor of medicine, consultant, Division of Hematology/Oncology, Mayo Clinic, highlights the recent treatment advances for patients with hepatocellular carcinoma.
Kabir Mody, MD, medical oncologist, Mayo Clinic, discusses treatment options for patients with hepatocellular carcinoma.
Advertisement
Latest Updated Articles
Dr. Mody on Progress Made With Y-90 in Hepatocellular CarcinomaPublished: February 18th 2021 | Updated:
Dr. Mody Discusses Treatment Options for HCCPublished: November 13th 2018 | Updated:
Dr. Mody Highlights Treatment Advances in HCCPublished: February 8th 2019 | Updated:
Dr. Mody on the Unique Delivery Approach for Y-90 in HCCPublished: January 28th 2021 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
Nuvisertib Yields Strong Safety, Promising Efficacy in R/R Myelofibrosis
5